
Dr. Charles Vega and Dr. Michael Simon Discuss a Case Involving a High-Risk Patient With Influenza
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
-
Narrado por:
-
De:
While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving treatment effectiveness, especially in pediatric and adolescent patients. In this podcast series, expert clinicians will discuss the latest evidence regarding the use of antiviral agents for the treatment of patients with influenza who are at normal or high risk for complications and the use of antiviral agents for influenza treatment based on their efficacy and ability to reduce the transmission of the disease.
For CME Credit, click here: https://tinyurl.com/pediatricss1e3